Drug – bio-affecting and body treating compositions – Plant material or plant extract of undetermined constitution... – Containing or obtained from a root – bulb – tuber – corm – or...
Reexamination Certificate
2000-02-08
2001-09-18
Lilling, Herbert J. (Department: 1651)
Drug, bio-affecting and body treating compositions
Plant material or plant extract of undetermined constitution...
Containing or obtained from a root, bulb, tuber, corm, or...
Reexamination Certificate
active
06290995
ABSTRACT:
BACKGROUND OF THE INVENTION
This invention relates to new safe natural drug, which is prevention of cancer and control of cancer cells. Specifically, this invention provides methods for producing of Berberine and Baicalin.
Also, the present invention proved a new radioimmunoassay (RIA) method for precise determination of Berberine and Baicalin. The RIA is an efficient analytical method for large clinical programs including double blind analysis (DBA), and good clinical practice (GCP).
DESCRIPTION OF PRIOR ART
Cancer is the second leading cause of death in the United States, and the incidence of cancer continues to climb annually. In recent years, about 1 million new cases of cancer are diagnosed yearly in the U.S. About half million people and 7 million people of annual deaths in the U.S. and in the world, respectively.
Many reports indicated that the side effects of plant's anti cancer drugs are lower than chemical and antibiotic's anti cancer drugs, Therefore, the development of plant drug has progressed very fast now. Taxol, for example, is a novel anti cancer plant drug isolated from the needles and bark of the western yew, Taxus brevifolia. It is the prototype for a new class of antitumor drugs, which are characterized by their capacity to promote the assembly of microtubules. Clinical trials conducted in the late 1980s and early 1990s demonstrated impressive clinical activities against advanced ovarian and breast cancer.
However, taxol has two big problems. The first problem is that natural source of taxol is very limited. And the second problem is that taxol is a poor-water soluble. Vehicles for parental administration on taxol cause serious side effects.
The most remarkable progress in the last 25 years has been in cancer biology. Now we understand what is required to turn a normal cell into a cancer cell. Cancer arises when a single cell changes so that it divides continuously, released from the controls that constrain the replication of normal cells. This transformation is due to changes in the function and activity of genes, which are segments of DNA. Of the 100,000 genes found in the human genome, only the altered activities of a small number of genes are responsible for transforming a normal cell into a cancer cell. These genes normally function to instruct cells to produce accelerators that drive cells to proliferate, brakes that control proliferation, or the repair of DNA damage or the elimination of damaged cells.
We now know that DNA changes are the fundamental cause of all cancers. These changes can occur due to chemicals, viruses, radiation and mistakes of duplicating DNA. When a normal cell recognizes damage to its DNA, it stops the process of growth and division. In the development of cancer, checkpoint controls are lost and the cell continues to divide, transmitting its damaged DNA to new cells.
Cancer does not develop at short time. The molecular changes necessary to transform a normal cell into a cancer cell may take years to accumulate. This is one reason for prevention of cancer by administering drugs that inhibit the crucial molecular events causing transformation.
The present invention disclosed that control process of turning a normal cell into a cancer cell by special natural and safe drugs. Recently a number of gene expression systems have been developed that can be regulated by the administration of specific small molecule drugs. It is important that the small molecule drugs are easily administered. Some of the earliest systems include exposure to heavy metal, and steroid hormones, but they are not suited for in vivo human. These systems, however, are suitable to study for the effect of small molecular drugs on controllable oncogenes, and to study for the treatment of cancer.
So far, no one drug has been succeeded to treat or prevent cancer by control cancer cells and without adverse side effects.
SUMMARY OF THE INVENTION
A new safe pharmaceutical composition in accordance with the present invention for prevention cancer and control cancer cells comprises Berberine and Baicalin.
Methods of control cancer cells include inhibiting oncogenes, increasing activity of tumor suppressor, inhibiting cancer cells proliferation, inhibiting growth of transplanted cancer, inhibiting cancer incidence.
Also, the present invention proved a new radioimmunoassay (RIA) method for precise determination of Berberine and Baicalin. The RIA is an efficient analytical method for large clinical programs including double blind analysis (DBA), and good clinical practice (GCP).
DETAILED DESCRIPTION OF THE INVENTION
Recent developments in cancer research, more specifically, in molecular biology, biochemical aspects, indicated that controlling cancer cells is more important. For example, control oncogene expression, apoptosis, and differentiation of cancer cells are several key steps in process of control cancer. The control of oncogene expression, apoptosis and differentiation of cancer is focus in cancer biology and molecular pharmacology of anticancer drug. For example, concentration of oncogene c-myc and c-myb RNA is rapid increased in human leukemia and other cancer cell, and a rapid decline in the expression of c-myc and c-myb RNA was seen in cancer cells induced to differentiate. Control oncogene expression, apoptosis and differentiation of cancer cells can control and preventing carcinogenesis.
The compositions of drugs and the sources of its components are listed as below.
TABLE 1
Component
Source
Berberine (BE)
Berberis poiretii
Schined
Berberis julianae
Schneid
Berberis soulieana
Schined
Berberis wilsonae
Schined
Baicalin (BA)
Scutellaria baicalensis
Georgi
Scutellaria scordifolia
Fisch
TABLE 1
Component
Source
Berberine (BE)
Berberis poiretii
Schined
Berberis julianae
Schneid
Berberis soulieana
Schined
Berberis wilsonae
Schined
Baicalin (BA)
Scutellaria baicalensis
Georgi
Scutellaria scordifolia
Fisch
REFERENCES:
patent: 5443839 (1995-08-01), Meybeck
patent: 5447719 (1995-09-01), Kamataki
patent: 5643598 (1997-07-01), Meybeck
patent: 6083921 (2000-07-01), Xu
Computer West JPAB Abstract JP360274 35 Tsuboi et al “Extracting Method for Extract with High Baicalein Content”, Feb. 8, 1988.*
Computer West JPAB Abstract JP361050921“Purification of Baicalin”, Mar. 1986.*
Computer West JPAB Abstract JP36105918 “Liquid Composition Containning Baicalin or Baicalein and External Drug for Skin or Skin Cosmetic Containing Same”, Jan. 1986.*
Computer West DWPI Abstract 1994-034629 EP642793 Fukuda et al “Apoptosis-Inducing Compsn Containing Baicalin or Baicalein-Induces Apopptosis in Cancer and Virally Infected Cells” Mar. 29, 1995.*
Computer West DWPI Abstract 1988-073860 JP63027435 “Extracting Extract Contg. High Baicalein Content by Adding Water to Powder of Scutellaria Root and Standing at Elevated Temp., Before EXTN., Used to Treat ECzema and Dermatitis”, Feb. 1988.*
Computer West DWPI Abstract 1984-007494 “Plant Extract Prepn Effective for Treating Arteriosclerosis, Apoplexy, Encephalomalcia and Hypdercholesterolaemia”, Feb. 1988.
LandOfFree
Plant drug for preventing cancer II does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Plant drug for preventing cancer II, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Plant drug for preventing cancer II will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2450761